FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591709377> ?p ?o ?g. }

• W2591709377 endingPage "847" @default.
• W2591709377 startingPage "836" @default.
• W2591709377 abstract "Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects.In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard-of-care chemotherapy. The primary end point was overall survival.Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients) or chemotherapy (134 patients), 376 patients received at least one dose. Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group (hazard ratio for death with blinatumomab vs. chemotherapy, 0.71; 95% confidence interval [CI], 0.55 to 0.93; P=0.01). Remission rates within 12 weeks after treatment initiation were significantly higher in the blinatumomab group than in the chemotherapy group, both with respect to complete remission with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hematologic recovery (44% vs. 25%, P<0.001). Treatment with blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month estimates, 31% vs. 12%; hazard ratio for an event of relapse after achieving a complete remission with full, partial, or incomplete hematologic recovery, or death, 0.55; 95% CI, 0.43 to 0.71; P<0.001), as well as a longer median duration of remission (7.3 vs. 4.6 months). A total of 24% of the patients in each treatment group underwent allogeneic stem-cell transplantation. Adverse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients in the chemotherapy group.Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B-cell precursor ALL. (Funded by Amgen; TOWER ClinicalTrials.gov number, NCT02013167 .)." @default.
• W2591709377 created "2017-03-16" @default.
• W2591709377 creator A5000436961 @default.
• W2591709377 creator A5002489867 @default.
• W2591709377 creator A5003034197 @default.
• W2591709377 creator A5004450449 @default.
• W2591709377 creator A5005591514 @default.
• W2591709377 creator A5009431453 @default.
• W2591709377 creator A5012101254 @default.
• W2591709377 creator A5013754928 @default.
• W2591709377 creator A5018106790 @default.
• W2591709377 creator A5020684790 @default.
• W2591709377 creator A5026967725 @default.
• W2591709377 creator A5029918677 @default.
• W2591709377 creator A5050256347 @default.
• W2591709377 creator A5055401685 @default.
• W2591709377 creator A5061124996 @default.
• W2591709377 creator A5067318724 @default.
• W2591709377 creator A5072568698 @default.
• W2591709377 creator A5075073484 @default.
• W2591709377 creator A5076898261 @default.
• W2591709377 creator A5078817313 @default.
• W2591709377 creator A5082611606 @default.
• W2591709377 creator A5082725388 @default.
• W2591709377 creator A5082785244 @default.
• W2591709377 creator A5084354003 @default.
• W2591709377 creator A5090435894 @default.
• W2591709377 creator A5091739351 @default.
• W2591709377 date "2017-03-02" @default.
• W2591709377 modified "2023-10-17" @default.
• W2591709377 title "Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia" @default.
• W2591709377 cites W1195517392 @default.
• W2591709377 cites W1488000644 @default.
• W2591709377 cites W1488910200 @default.
• W2591709377 cites W1600925615 @default.
• W2591709377 cites W1879221139 @default.
• W2591709377 cites W1967348190 @default.
• W2591709377 cites W1967512987 @default.
• W2591709377 cites W1970050467 @default.
• W2591709377 cites W1975280591 @default.
• W2591709377 cites W1977380325 @default.
• W2591709377 cites W1984079088 @default.
• W2591709377 cites W1988623079 @default.
• W2591709377 cites W1991184842 @default.
• W2591709377 cites W1999573477 @default.
• W2591709377 cites W2015956932 @default.
• W2591709377 cites W2017838975 @default.
• W2591709377 cites W2026177698 @default.
• W2591709377 cites W2039642633 @default.
• W2591709377 cites W2054727430 @default.
• W2591709377 cites W2055482234 @default.
• W2591709377 cites W2059707463 @default.
• W2591709377 cites W2081127271 @default.
• W2591709377 cites W2083494119 @default.
• W2591709377 cites W2099570622 @default.
• W2591709377 cites W2107925822 @default.
• W2591709377 cites W2116555417 @default.
• W2591709377 cites W2118796952 @default.
• W2591709377 cites W2123755151 @default.
• W2591709377 cites W2127742735 @default.
• W2591709377 cites W2129702476 @default.
• W2591709377 cites W2132827894 @default.
• W2591709377 cites W2141019574 @default.
• W2591709377 cites W2166295047 @default.
• W2591709377 cites W2318792343 @default.
• W2591709377 cites W2334417343 @default.
• W2591709377 cites W2419639370 @default.
• W2591709377 cites W2520695016 @default.
• W2591709377 cites W2594087813 @default.
• W2591709377 cites W4237606124 @default.
• W2591709377 cites W4242589154 @default.
• W2591709377 cites W4372230389 @default.
• W2591709377 doi "https://doi.org/10.1056/nejmoa1609783" @default.
• W2591709377 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5881572" @default.
• W2591709377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28249141" @default.
• W2591709377 hasPublicationYear "2017" @default.
• W2591709377 type Work @default.
• W2591709377 sameAs 2591709377 @default.
• W2591709377 citedByCount "1317" @default.
• W2591709377 countsByYear W25917093772017 @default.
• W2591709377 countsByYear W25917093772018 @default.
• W2591709377 countsByYear W25917093772019 @default.
• W2591709377 countsByYear W25917093772020 @default.
• W2591709377 countsByYear W25917093772021 @default.
• W2591709377 countsByYear W25917093772022 @default.
• W2591709377 countsByYear W25917093772023 @default.
• W2591709377 crossrefType "journal-article" @default.
• W2591709377 hasAuthorship W2591709377A5000436961 @default.
• W2591709377 hasAuthorship W2591709377A5002489867 @default.
• W2591709377 hasAuthorship W2591709377A5003034197 @default.
• W2591709377 hasAuthorship W2591709377A5004450449 @default.
• W2591709377 hasAuthorship W2591709377A5005591514 @default.
• W2591709377 hasAuthorship W2591709377A5009431453 @default.
• W2591709377 hasAuthorship W2591709377A5012101254 @default.
• W2591709377 hasAuthorship W2591709377A5013754928 @default.
• W2591709377 hasAuthorship W2591709377A5018106790 @default.
• W2591709377 hasAuthorship W2591709377A5020684790 @default.
• W2591709377 hasAuthorship W2591709377A5026967725 @default.

• next